100 results
Page 2 of 5
8-K
EX-99.1
rncsyzlvcv 1irhla
28 Feb 22
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
8:26am
424B5
tpm8f
17 Feb 22
Prospectus supplement for primary offering
8:59am
8-K
EX-99.1
qnre6 fzkf90c1
10 Jan 22
Regulation FD Disclosure
8:27am
8-K
EX-99.2
5um87vf7w jggz2
29 Nov 21
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
7:04am
8-K
EX-10.1
hcj8f5rtjllnm84u
28 Jul 21
Other Events
4:15pm
8-K
EX-10.2
cks d2wwnrng
28 Jul 21
Other Events
4:15pm
8-K
EX-99.1
pik7 fhmt9fksaky
16 Jun 21
FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
5:14pm
8-K
EX-99.1
xieqssthq2jsiic
17 May 21
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
8:30am
8-K
EX-99.1
siq txm48g61lv
12 Apr 21
Regulation FD Disclosure
7:40am
8-K
EX-99.1
rtfox8r4289
17 Feb 21
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
8:00am
8-K
j1yrfhq01uan mtvjaxj
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
8-K
EX-99.2
qicdue8 cj3xcgtaeje
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
8-K
EX-99.1
p0sfa ei127b12y
11 Jan 21
Entry into a Material Definitive Agreement
8:20am